Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Escape Cancer, but Age Sooner? Scientists Unravel the Dark Side of the Tumor Suppressing Process

03.12.2008
Cells shut down and stop dividing when their DNA is damaged, providing protection against cancer.

However, a new study has found these cells also spew proteins into the cells’ surrounding environment. The process, called cellular senescence, causes inflammation and sets up conditions that support the development of age-related diseases including, ironically, cancer.

The findings, by Buck Institute scientists, mark the first comprehensive molecular description of a paradoxical process that prevents cancer in younger people, but promotes age-related cancers and other maladies later in life. The findings appear in the December 2, 2008 edition of the on-line, open access journal PLoS Biology.

“We provide for the first time a broad molecular description of how this well known mechanism for cancer prevention drives aging and age-related disease by changing the local tissue environment,” said Buck Faculty member Judith Campisi, PhD, lead author of the study who is also Senior Scientist at Lawrence Berkeley National Laboratory.

The study shows that the senescent cells secrete inflammatory, growth stimulating, immunomodulatory, and other proteins that dramatically change the tissue microenvironment, both in cell culture and in response to DNA-damaging chemotherapy in human patients. The human data compared tissue samples from prostate cancer patients that were obtained prior to and after completing chemotherapy.

The study also showed that normal cells that acquire a highly active mutant version of a cancer-promoting protein known as RAS secrete higher levels of the tissue-altering molecules, as do cells that lose functions of the tumor suppressor protein p53. The study explains why senescent cells promote the growth and aggressiveness of nearby precancerous or cancer cells, and further defines a new mechanism by which precancerous or cancer cells that have lost the p53 tumor suppressor, or gained an oncogene such as RAS, promote cancer so efficiently.

“This study defines a new paradigm for how oncogenes promote, and how tumor suppressor genes suppress the development of cancer,” said Campisi. “The established role for these genes is to control the cell itself. Our findings show that both types of genes also strongly change the tissue microenvironment, and therefore control cancer by mechanisms that depend not only on the response of the affected cells themselves, but also on the response of neighboring cells, or the local tissue environment.” Campisi said the findings also help explain why cancer patients feel so sick when they get chemotherapy. “Chemotherapy is brutal -- both normal and cancerous cells are forced into senescence, with resulting secretion of inflammatory factors that can produce flu-like symptoms during treatment,” Campisi said.

While Campisi emphasizes that chemotherapy can cure cancer, she says the study provides a cautionary note for younger patients who receive treatments that could promote the development of further cancers later in life. Campisi said the study points out the need for new biologically targeted therapies for cancer that exploit more specific differences between normal and cancer cells. Current DNA damaging chemotherapy focuses on cells that divide rapidly -- impacting cancer cells, as well as all dividing cells including cells in the alimentary canal and hair follicles.

The study has major implications for age research. Campisi adds, “This dynamic between cancer prevention and aging is exactly what is predicted by antagonistic pleiotropy, a major evolutionary theory of aging, which explains the trade-offs between early fitness and late life survival.” The results suggest that a cellular response that likely evolved to protect from early life cancer can promote late life pathology, including, ironically, late life cancer. The challenge now is to preserve the anti-cancer activity of the senescence response while dampening its pro-aging effects.

The next phase of the ongoing research involves efforts to encourage the body to eliminate senescent cells more rapidly than it normally does. “That’s got to be the goal,” said Campisi. “Although senescent cells exist for the good purpose of preventing cancer, we don’t want them to hang around – we want the body to be able to get rid of them.”

Other researchers involved in the study include Francis Rodier and Denise P. Muñoz of the Buck Institute, along with Jean-Philippe Coppé, Christopher K. Patil, and Joshua Goldstein (now at the Novartis Research Foundation) of the Life Sciences Division of Lawrence Berkeley National Laboratory, Berkeley CA; Pierre-Yves Desprez of the California Pacific Medical Center, San Francisco CA; and Yun Sun and Peter S. Nelson of the Fred Hutchinson Cancer Research Center, Seattle, WA. The work was supported by grants from the National Institutes of Health, the Pacific Northwest Prostate Cancer Specialized Programs of Research Excellence, and the Larry L. Hillblom Foundation.

About the Buck Institute:

The Buck Institute is the only freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individual’s life. The National Institute on Aging designated the Buck a “Nathan Shock Center of Excellence in the Biology of Aging,” one of just five centers in the country. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimer’s and Parkinson’s disease, cancer, diabetes and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For more information: http://www.buckinstitute.org.

Kris Rebillot | Newswise Science News
Further information:
http://www.buckinstitute.org

More articles from Health and Medicine:

nachricht On track to heal leukaemia
18.01.2017 | Universitätsspital Bern

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

A big nano boost for solar cells

18.01.2017 | Power and Electrical Engineering

Glass's off-kilter harmonies

18.01.2017 | Materials Sciences

Toward a 'smart' patch that automatically delivers insulin when needed

18.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>